Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 12/20 | 0.42 |
| ▸ | DPP8 | Q6V1X1 | 8/20 | 0.42 |
| ▸ | DPP9 | Q86TI2 | 7/20 | 0.42 |
| ▸ | TERT | O14746 | 1/20 | 0.38 |
| ▸ | DPP7 | Q9UHL4 | 7/20 | 0.38 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.38 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.38 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2142253 | 1.00 | DPP4 (0.42) | DPP4DPP8DPP9TERTDPP7 | |
| SCHEMBL3663068 | 0.82 | DPP4 (0.44) | DPP4DPP8DPP9TERTDPP7 | |
| SCHEMBL1770627 | 0.78 | DPP4 (0.44) | DPP4DPP8DPP9DPP7 | |
| SCHEMBL9650387 | 0.78 | DPP4 (0.44) | DPP4DPP8DPP9TERTDPP7 | |
| SCHEMBL9969913 | 0.78 | DPP4 (0.44) | DPP4DPP8DPP9TERTDPP7 | |
| SCHEMBL1770623 | 0.78 | DPP4 (0.44) | DPP4DPP8DPP9DPP7 | |
| SCHEMBL76741 | 0.78 | DPP4 (0.44) | DPP4DPP8DPP9DPP7 | |
| SCHEMBL200229 | 0.78 | DPP4 (0.44) | DPP4DPP8DPP9TERTDPP7 | |
| SCHEMBL8122591 | 0.78 | DPP4 (0.44) | DPP4DPP8DPP9TERTDPP7 | |
| SCHEMBL6686776 | 0.78 | DPP4 (0.44) | DPP4DPP8DPP9TERTDPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8541462-B2 | Tetrahydrocarbazole derivatives as ligands of G-protein coupled receptors | AETERNA ZENTARIS GMBH (DE) | 2013-09-24 | — | — | US | disclosed |
| US-20120122763-A1 | NOVEL TETRAHYDROCARBAZOLE DERIVATIVES AS LIGANDS OF G-PROTEIN COUPLED RECEPTORS | AETERNA ZENTARIS GMBH (DE) | 2012-05-17 | — | — | US | disclosed |
| US-8148546-B2 | Tetrahydrocarbazole derivatives as ligands of G-protein coupled receptors | AETERNA ZENTARIS GMBH (DE) | 2012-04-03 | — | — | US | disclosed |
| EP-2150558-A1 | NOVEL TETRAHYDROCARBAZOLE DERIVATIVES AS LIGANDS OF G-PROTEIN COUPLED RECEPTORS | AEterna Zentaris GmbH (DE) | 2010-02-10 | — | — | EP | disclosed |
| US-20090170783-A1 | NOVEL TETRAHYDROCARBAZOLE DERIVATIVES AS LIGANDS OF G-PROTEIN COUPLED RECEPTORS | AETERNA ZENTARIS GMBH (DE) | 2009-07-02 | — | — | US | disclosed |
| WO-2008132153-A1 | NOVEL TETRAHYDROCARBAZOLE DERIVATIVES AS LIGANDS OF G-PROTEIN COUPLED RECEPTORS | ÆTERNA ZENTARIS GMBH (DE) | 2008-11-06 | — | — | WO | disclosed |
| EP-1988098-A1 | Novel Tetrahydrocarbazole Derivatives as Ligands of G-protein Coupled Receptors | AEterna Zentaris GmbH (DE) | 2008-11-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170783-A1 | NOVEL TETRAHYDROCARBAZOLE DERIVATIVES AS LIGANDS OF G-PROTEIN COUPLED RECEPTORS | GPR88, GPR34, GPR27 | DPP4 3173/4885DPP8 2833/4885DPP9 2374/4885 |
| US-20120122763-A1 | NOVEL TETRAHYDROCARBAZOLE DERIVATIVES AS LIGANDS OF G-PROTEIN COUPLED RECEPTORS | GPR88, GPR34, GPR27 | DPP4 3173/4885DPP8 2833/4885DPP9 2374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.